<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427960</url>
  </required_header>
  <id_info>
    <org_study_id>D3560L00060</org_study_id>
    <secondary_id>SHUKRA</secondary_id>
    <nct_id>NCT00427960</nct_id>
  </id_info>
  <brief_title>Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg</brief_title>
  <official_title>A Phase IV, 6-week, Randomised, Double-blind, Multicentre, Parallel Group, Comparative Study to Evaluate the Efficacy of Rosuvastatin 5mg and Atorvastatin 10mg in UK Asian Subjects With Primary Hypercholesterolaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and safety of rosuvastatin 5mg in
      lowering blood cholesterol, compared to one other medicine, atorvastatin 10mg in Asian
      patients in the UK.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to inadequate recruitment
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Low Density Lipoprotein - Cholesterol (LDL-C)</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Calculated as LDL-C at Week 6 - LDL-C at Week 12] * 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Reaching the General Medical Services (GMS) Contract Target of Total Cholesterol (TC) &lt;5 mmol/L</measure>
    <time_frame>6 weeks (Baseline) and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Reaching the Joint British Societies' Guideline (JBS 2) Targets of TC &lt;4 mmol/L and LDL-C &lt;2 mmol/L</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Reaching the European (EAS) Targets of LDL-C&lt;2.5 or 3.00 mmol/L, Depending on Risk Category, and the Combined LDL-C and TC Target of LDL-C&lt;2.5 or 3.0 mmol/L and TC&lt;4.5 or 5.0 mmol/L, Both Depending on Risk Category.</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Risk categories are:
Symptomatic Asymptomatic, total risk &lt;5% Asymptomatic, total risk ≥5%, baseline LDL-C&lt;3 mmol/L and baseline TC&lt;5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L
Patients are defined as symptomatic if they meet at least 1 of the following criteria:
History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg
Total risk is derived from age, sex, TC, systolic BP and smoking status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change From Baseline(week6) in TC</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change From Baseline (Week 6) in High-density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Reaching the Joint British Societies Guideline (JBS 2) Target of TC &lt;4 mmol/L</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change From Baseline (Week 6)in Non-HDL-C</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change From Baseline (Week 6) in Apolipoprotein-B (ApoB)</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change From Baseline (Week 6) in Apolipoprotein-A1 (ApoA1)</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change From Baseline (Week 6)in LDL-C/HDL-C Ratio</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change From Baseline (Week 6) in TC/HDL-C Ratio</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change From Baseline(Week 6) in Non-HDL-C/HDL-C Ratio</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change From Baseline (Week 6) in ApoB/ApoA1 Ratio</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Reaching the European (EAS) Targets of LDL-C&lt;2.5 or 3.00 mmol/L, Depending on Risk Category.</measure>
    <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
    <description>Risk categories are:
Symptomatic Asymptomatic, total risk &lt;5% Asymptomatic, total risk ≥5%, baseline LDL-C&lt;3 mmol/L and baseline TC&lt;5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L
Patients are defined as symptomatic if they meet at least 1 of the following criteria:
History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg
Total risk is derived from age, sex, TC, systolic BP and smoking status.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Hypercholesterolaemia</condition>
  <arm_group>
    <arm_group_label>rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rosuvastatin 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary advice</intervention_name>
    <arm_group_label>rosuvastatin</arm_group_label>
    <arm_group_label>atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>rosuvastatin 5 mg</description>
    <arm_group_label>rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>atorvastatin 10 mg</description>
    <arm_group_label>atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Self described Asian, first or second generation

          -  Male or female &gt; or = 18 years with primary hypercholesterolaemia.

        Exclusion Criteria:

          -  Use of cholesterol lowering drugs from visit 1

          -  Homozygous familial hypercholesterolaemia

          -  Active arterial disease within 3 months of study entry

          -  Poorly controlled diabetes

          -  Uncontrolled hypothyroidism

          -  Active liver disease

          -  History of alcoh/drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rhiannon Rowsell, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shahid Ali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bradford PCT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Allerton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blackburn</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bolton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Crawley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research SIte</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research SIte</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research SIte</name>
      <address>
        <city>Slough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>March 25, 2009</results_first_submitted>
  <results_first_submitted_qc>March 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2010</results_first_posted>
  <last_update_submitted>November 30, 2010</last_update_submitted>
  <last_update_submitted_qc>November 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2010</last_update_posted>
  <keyword>cholesterol</keyword>
  <keyword>statin</keyword>
  <keyword>Asian</keyword>
  <keyword>LDL-cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 25 primary and secondary care centres in the United Kingdom. The first participant was enrolled on 20th December 2006 and the last participant entered the study on 16th November 2007.</recruitment_details>
      <pre_assignment_details>Participants entered an initial 6-week dietary run-in/ wash-out period, after which those with a fasting low density lipoprotein cholesterol (LDL-C) of greater than or equal to 4.00 mmol/L and triglycerides (TG) less than 4.52 mmol/L, were randomised to receive treatment with either rosuvastatin 5 mg plus atorvatstatin , or atorvastatin 10mg</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rosuvastatin</title>
          <description>rosuvastatin 5 mg</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin</title>
          <description>atorvastatin 10 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosuvastatin</title>
          <description>rosuvastatin 5 mg</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin</title>
          <description>atorvastatin 10 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="11"/>
                    <measurement group_id="B2" value="53" spread="11"/>
                    <measurement group_id="B3" value="51.5" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Low Density Lipoprotein - Cholesterol (LDL-C)</title>
        <description>Calculated as LDL-C at Week 6 - LDL-C at Week 12] * 100</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Low Density Lipoprotein - Cholesterol (LDL-C)</title>
          <description>Calculated as LDL-C at Week 6 - LDL-C at Week 12] * 100</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percent Change in LDL-C</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.28"/>
                    <measurement group_id="O2" value="36.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Reaching the General Medical Services (GMS) Contract Target of Total Cholesterol (TC) &lt;5 mmol/L</title>
        <time_frame>6 weeks (Baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Reaching the General Medical Services (GMS) Contract Target of Total Cholesterol (TC) &lt;5 mmol/L</title>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Reaching the Joint British Societies’ Guideline (JBS 2) Targets of TC &lt;4 mmol/L and LDL-C &lt;2 mmol/L</title>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Reaching the Joint British Societies’ Guideline (JBS 2) Targets of TC &lt;4 mmol/L and LDL-C &lt;2 mmol/L</title>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Reaching the European (EAS) Targets of LDL-C&lt;2.5 or 3.00 mmol/L, Depending on Risk Category, and the Combined LDL-C and TC Target of LDL-C&lt;2.5 or 3.0 mmol/L and TC&lt;4.5 or 5.0 mmol/L, Both Depending on Risk Category.</title>
        <description>Risk categories are:
Symptomatic Asymptomatic, total risk &lt;5% Asymptomatic, total risk ≥5%, baseline LDL-C&lt;3 mmol/L and baseline TC&lt;5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L
Patients are defined as symptomatic if they meet at least 1 of the following criteria:
History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg
Total risk is derived from age, sex, TC, systolic BP and smoking status.</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Reaching the European (EAS) Targets of LDL-C&lt;2.5 or 3.00 mmol/L, Depending on Risk Category, and the Combined LDL-C and TC Target of LDL-C&lt;2.5 or 3.0 mmol/L and TC&lt;4.5 or 5.0 mmol/L, Both Depending on Risk Category.</title>
          <description>Risk categories are:
Symptomatic Asymptomatic, total risk &lt;5% Asymptomatic, total risk ≥5%, baseline LDL-C&lt;3 mmol/L and baseline TC&lt;5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L
Patients are defined as symptomatic if they meet at least 1 of the following criteria:
History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg
Total risk is derived from age, sex, TC, systolic BP and smoking status.</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change From Baseline(week6) in TC</title>
        <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change From Baseline(week6) in TC</title>
          <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percent Change in TC</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.03"/>
                    <measurement group_id="O2" value="-26.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change From Baseline (Week 6) in High-density Lipoprotein Cholesterol (HDL-C)</title>
        <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change From Baseline (Week 6) in High-density Lipoprotein Cholesterol (HDL-C)</title>
          <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percent Change in HDL-C</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.46"/>
                    <measurement group_id="O2" value="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Reaching the Joint British Societies Guideline (JBS 2) Target of TC &lt;4 mmol/L</title>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Reaching the Joint British Societies Guideline (JBS 2) Target of TC &lt;4 mmol/L</title>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change From Baseline (Week 6)in Non-HDL-C</title>
        <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change From Baseline (Week 6)in Non-HDL-C</title>
          <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percent Change in Non-HDL-C</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.72"/>
                    <measurement group_id="O2" value="-34.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change From Baseline (Week 6) in Apolipoprotein-B (ApoB)</title>
        <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change From Baseline (Week 6) in Apolipoprotein-B (ApoB)</title>
          <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percent Change in ApoB</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.96"/>
                    <measurement group_id="O2" value="-28.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change From Baseline (Week 6) in Apolipoprotein-A1 (ApoA1)</title>
        <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change From Baseline (Week 6) in Apolipoprotein-A1 (ApoA1)</title>
          <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percent Change in ApoA1</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55"/>
                    <measurement group_id="O2" value="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change From Baseline (Week 6)in LDL-C/HDL-C Ratio</title>
        <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change From Baseline (Week 6)in LDL-C/HDL-C Ratio</title>
          <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percent Change in LDL-C/HDL-C Ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.75"/>
                    <measurement group_id="O2" value="-38.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change From Baseline (Week 6) in TC/HDL-C Ratio</title>
        <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change From Baseline (Week 6) in TC/HDL-C Ratio</title>
          <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percent Change in TC/HDL-C Ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.99"/>
                    <measurement group_id="O2" value="-28.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change From Baseline(Week 6) in Non-HDL-C/HDL-C Ratio</title>
        <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change From Baseline(Week 6) in Non-HDL-C/HDL-C Ratio</title>
          <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percent Change in Non-HDL-C/HDL-C Ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.05"/>
                    <measurement group_id="O2" value="-35.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change From Baseline (Week 6) in ApoB/ApoA1 Ratio</title>
        <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change From Baseline (Week 6) in ApoB/ApoA1 Ratio</title>
          <description>Derived according to the following formula: 100*[Lipid at week 12 - Lipid at week 6]/Lipid at week 6</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percent Change in ApoB/ApoA1 Ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.89"/>
                    <measurement group_id="O2" value="-28.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Reaching the European (EAS) Targets of LDL-C&lt;2.5 or 3.00 mmol/L, Depending on Risk Category.</title>
        <description>Risk categories are:
Symptomatic Asymptomatic, total risk &lt;5% Asymptomatic, total risk ≥5%, baseline LDL-C&lt;3 mmol/L and baseline TC&lt;5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L
Patients are defined as symptomatic if they meet at least 1 of the following criteria:
History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg
Total risk is derived from age, sex, TC, systolic BP and smoking status.</description>
        <time_frame>6 weeks (baseline) and 12 weeks</time_frame>
        <population>Intention to treat (ITT) population (all randomized patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Reaching the European (EAS) Targets of LDL-C&lt;2.5 or 3.00 mmol/L, Depending on Risk Category.</title>
          <description>Risk categories are:
Symptomatic Asymptomatic, total risk &lt;5% Asymptomatic, total risk ≥5%, baseline LDL-C&lt;3 mmol/L and baseline TC&lt;5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L
Patients are defined as symptomatic if they meet at least 1 of the following criteria:
History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg
Total risk is derived from age, sex, TC, systolic BP and smoking status.</description>
          <population>Intention to treat (ITT) population (all randomized patients).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7"/>
                    <measurement group_id="O2" value="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosuvastatin</title>
          <description>rosuvastatin 5 mg</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin</title>
          <description>atorvastatin 10 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4"/>
                <counts group_id="E2" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>The study achieved only 8% of the randomised target number of patients and for this reason alone was terminated early. Planned statistical analyses could not be performed. No scientifically valid conclusions can be drawn from the limited study data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>Astrazeneca</organization>
      <email>AZTrial_Results_Posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

